Compare MAT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAT | ACAD |
|---|---|---|
| Founded | 1945 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 1994 | 2000 |
| Metric | MAT | ACAD |
|---|---|---|
| Price | $14.08 | $21.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | $20.90 | ★ $30.55 |
| AVG Volume (30 Days) | ★ 4.0M | 1.4M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 0.20 | 0.02 |
| Revenue | ★ $5,347,623,000.00 | $726,437,000.00 |
| Revenue This Year | $5.92 | $18.80 |
| Revenue Next Year | $5.08 | $11.70 |
| P/E Ratio | ★ $71.00 | $1,086.08 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $14.03 | $19.69 |
| 52 Week High | $22.48 | $28.35 |
| Indicator | MAT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 49.69 |
| Support Level | N/A | $21.12 |
| Resistance Level | $15.38 | $22.03 |
| Average True Range (ATR) | 0.44 | 0.62 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 6.42 | 74.70 |
Mattel manufactures and markets toy products that are sold to its wholesale partners and direct to retail customers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2025, with the remainder stemming from international markets.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.